LQDA 144 SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

LQDA ▲ +39.11% at T+20d

NEUTRAL call ✓ call won +39.11% · α vs SPY +33.29% · entry $41.40 → $57.59

Next anchor: T+60d in 25d

Last close $71.23 (close Jun 12) · +72.05% from $41.40 entry

Entry anchored
Apr 15, 03:59 PM ET
via Databento tick

T+1d

-4.66%

call -4.66% · α -5.88%

$39.47

settled 2mo ago

T+5d

-9.52%

call -9.52% · α -10.50%

$37.46

settled 8w ago

T+20d

+39.11%

call +39.11% · α +33.29%

$57.59

settled 5w ago

T+60d

—

call — · α —

—

in 25d

Price Chart

Loading chart...

Executive Summary

Roger Jeffs, a director and officer of Liquidia Corp, filed a Form 144 to sell up to 24,733 shares of common stock, valued at approximately $132,000. The sale is part of a 10b5-1 plan for Serendipity Biopharma LLC, an entity affiliated with Jeffs. This filing is an advance notice and does not confirm the sale has occurred.

Actionable Insight

Monitor for actual Form 4 filings to confirm if and when the sale occurs. Given the small size relative to market cap and the ongoing 10b5-1 plan context, this notice alone is unlikely to move the stock. However, continued insider selling could signal reduced confidence.

Key Facts

Roger Jeffs, Director and Officer of Liquidia Corp, is the reporting owner.
Form 144 filed for 24,733 shares of common stock, with an estimated value of $132,000.
Sale is conducted under a 10b5-1 plan for Serendipity Biopharma LLC, an affiliated entity.
No actual sale has occurred yet; this is a notice of proposed sale.
Recent insider selling activity includes $3.9M in sales over the past 30 days.

Financial Impact

Approximately $132,000 in potential stock sale, representing a small fraction of Liquidia's $3.4B market cap.

dilutioninsider ownership

Risk Factors

Perception of insider selling may negatively influence investor sentiment, especially amid recent $3.9M in insider outflows.
If sales proceed near-term, increased supply could pressure the stock price, particularly in low-volume trading environments.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

Document	Accession Number
144 Filing (Primary)	0001950047-26-003494
Document: 0001950047-26-003494-index.html	0001950047-26-003494
Document: 0001950047-26-003494.txt	0001950047-26-003494

32 reports for LQDA

T+1T+5T+20T+60

82% Hit rate 9 of 11 directional calls best @ T+60▲ +70.18%Mar 5, 2026

Filters

Reports for LQDA — sortable, filterable
	Type				Now
Jun 11, 2026 4d ago	Institutional Cluster BULLISH ★ 5/10	$65.50 awaiting T+1	awaiting T+1	—	$71.23 (+8.75%)
Jun 10, 2026 4d ago	144 BEARISH ★ 5/10	$65.21 awaiting T+1	awaiting T+1	—	$71.23 (−9.23%)
Jun 8, 2026 6d ago	Insider Cluster NEUTRAL ★ 3/10	$63.94 awaiting T+1	awaiting T+1	—	$71.23 (+11.40%)
Jun 8, 2026 6d ago	CLUSTER / 8-K NEUTRAL ★ 5/10	$63.94 awaiting T+1	awaiting T+1	—	$71.23 (+11.40%)
Jun 4, 2026 10d ago	144 BEARISH ★ 6/10	$62.76 awaiting T+1	awaiting T+1	—	$71.23 (−13.50%)
Jun 4, 2026 10d ago	144 BEARISH ★ 5/10	$62.76 awaiting T+1	awaiting T+1	—	$71.23 (−13.50%)
Jun 3, 2026 11d ago	Insider Cluster NEUTRAL ★ 3/10	$62.54 $61.85	▼ −1.10%	▲ +1.50%	$71.23 (+13.90%)
Jun 1, 2026 13d ago	144 NEUTRAL ★ 4/10	$58.75 $55.11	▼ −6.20%	▼ −6.34%	$71.23 (+21.24%)
May 26, 2026 19d ago	Insider Cluster NEUTRAL ★ 4/10	$62.03 $62.03	· 0.00%	▼ −0.55%	$71.23 (+14.83%)
May 21, 2026 25d ago	Insider Cluster MIXED ★ 5/10	$61.97 $60.98	▼ −1.60%	▼ −2.04%	$71.23 (+14.94%)

US Market Status

Market Closed — Opens in 41m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access